Dr. Renu Razdan of Max Neeman International Speaks at Lilly Women India Network Event

   Dr. Renu Razdan of Max Neeman International Speaks at Lilly Women India
                                Network Event

PR Newswire

RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2013

RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2013 /PRNewswire/ --Max Neeman
International announced today that Chief Operating Officer, Dr. Renu Razdan
was a guest speaker at the Lilly Women Network event in India, October 10^th.
Dr. Razdan shared her success story as an upper-level executive of the leading
Indian CRO; her journey through leadership, the challenges faced as a woman
and the skills she honed to overcome those challenges.

Lilly Women India Network is a platform for women employees to interact,
exchange ideas, educate and empower each other to enhance lives and foster
professional success.

"Max Neeman and Eli Lilly [India] have shared a positive working relationship
for years and I am honored to speak with their female employees regarding my
own personal journey to success. Max Neeman's corporate culture has
encouraged, valued and acknowledged my hard work and efforts, allowing me to
become the COO I am today," said Dr. Razdan.

Dr. Razdan joined the company in 2005 and is responsible for oversight of
Operations Departments as well as heading the Business Development team in
India for client relations in Europe and South East Asia. She brings over ten
years of experience and has played an active role in the development and
growth of the company. Prior to joining Max Neeman International, Dr. Razdan
worked at Ranbaxy Laboratories Limited for six years, pursued ICRETT
Fellowship of UICC Geneva, an international agency for research on cancer,
Lyon (France), and G.S.F. Fellowship at German Cancer Research Centre (DKFZ),
Heidelberg (Germany).

About Max Neeman International
'Max Neeman' is a leading Asia-Pacific CRO with India expertise and expanded
capabilities into N. America and Europe. Since 2001, the company has provided
clinical research services for the successful conduct of drug and device
trials in compliance with ICH GCP standards. The company is ISO 9001:2008
certified for monitoring, site management and data management with over >400
employees, 245 active sites in various therapeutic areas and 310 trials
awarded. Data Management services alone have touched 60 countries. For more
information contact Donald Swankie, Vice President USA:919-424-3345
donald.swankie@neeman-medical.com or go to www.neeman-medical.com.



SOURCE Max Neeman International

Website: http://www.neeman-medical.com
 
Press spacebar to pause and continue. Press esc to stop.